A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
Refereed conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者LIM Ho Yeong, YEN Chia Jui, TAK Won Young, HEO Jeong, CHOI Hye Jin, LIN Cheng Yao, YOON Jung Hwan, HSU Chiun, RAU Kun Ming, POON Ronnie, YEO Winnie, PARK Joong Won, TAY Miah Hiang, HSIEH Wen Son, KAPPELER Christian, RAJAGOPALAN Prabhu, KRISSEL Heiko
會議名稱Annual Meeting of the American Society of Clinical Oncology
會議開始日01.06.2012
會議國家/地區美國
會議論文集題名Annual Meeting of the American Society of Clinical Oncology
出版年份2012
月份6
出版地United States of America
頁次1
語言英式英語
關鍵詞unresectable hepatocellular carcinoma

上次更新時間 2018-20-01 於 07:36